Autologous Platelet Concentrate as a Treatment for Horses with Refractory Fetlock Osteoarthritis

Osteoarthritis (OA) is one of the most common musculoskeletal pathologies in horses and is a disease capable of halting their athletic career. Clinically, OA can be a difficult problem to deal with, particularly when there is no longer a positive response to corticosteroids or rest. In order to avoid further articular tissue degeneration, which could lead to the loss of the joint function, novel therapies are focusing not only on controlling inflammation and pain but also on tissue healing and repair. Autologous platelet concentrate (PC) growth factors are known to have anabolic and angiogenic properties and a positive effect on synovial epithelium, cartilage, and pain. The aim of this study was to analyze the clinical outcome of horses with OA treated with PC. Selected cases were treated only with PC, and they all belong to the same sport activity. We show here the method for PC preparation, follow-up evaluation, and outcome of 20 cases with refractory OA treated exclusively with autologous PC. After a 1-year follow-up, 80% of patients were able to resume work. According to our results and observations, PC can be used as a safe and low-cost intra-articular therapy for refractory OA in the horse.